



réanimation 2023

PARIS 14-16 JUIN

Palais des Congrès de Paris
Porte Maillot


RAAC et réa, une contradiction?

Antoine Dewitte

Service d'Anesthésie-Réanimation Groupe Sud

CHU de Bordeaux

Immunoconcept, CNRS UMR 5164



réanimation 2023

PARIS 14-16 JUIN

Palais des Congrès de Paris
Porte Maillot

Déclaration de liens

**Mon intervention ne présente aucun
conflit d'intérêt**

Récupération améliorée après chirurgie

Organisation
spécifique des soins
selon un «**chemin
clinique**»

Informer le patient et le former à la
démarche

Anticiper l'organisation des soins et la
sortie du patient

Réduire les conséquences du stress
chirurgical

Contrôler la douleur dans toutes les
situations

Favoriser et stimuler l'autonomie des
patients

En réanimation ?

Organisation
spécifique des soins
selon un «**chemin
clinique**»

~~Informer le patient et le famille à la
démarche~~


~~Anticiper l'organisation de soins et la
sortie du patient~~

~~Réduire les complications
chirurgicales~~

Contrôler la douleur dans toutes les
situations

Favoriser et stimuler l'autonomie des
patients

Récupération améliorée après chirurgie




Approche **multidisciplinaire** de prise en charge **globale**





« Apparition ou aggravation d'une ou de plusieurs déficiences physiques, cognitives et/ou mentales apparues après le séjour en réa et persistant après la sortie de l'hôpital »




Post Intensive Care Syndrome (PICS)



Long-term Cognitive Impairment and Functional Disability Among Survivors of Severe Sepsis

Dans une population âgée, le sepsis est associé à de nouvelles déficiences cognitives et incapacités fonctionnelles substantielles et persistantes chez les survivants

Time to sepsis admission, median (IQR), y
No. of patients



Post Intensive Care Syndrome (PICS)



Fatigue Symptoms During the First Year Following ARDS



Karin J. Neufeld, MD, MPH; Jeannie-Marie S. Leoutsakos, PhD, MHS; Haijuan Yan, PhD; Shihong Lin, MS; Jeffrey S. Zabinski, MD; Victor D. Dinglas, MPH; Megan M. Hosey, PhD; Ann M. Parker, MD; Ramona O. Hopkins, PhD; and Dale M. Needham, MD, PhD



Les déficiences physiques et mentales sont étroitement associées




The impact of extended bed rest on the musculoskeletal system in the critical care environment

Selina M. Parry^{1*} and Zudin A. Puthuchear^{2,3}

Réductions de la **masse musculaire et de la densité osseuse**, en parallèle, des altérations des autres systèmes du corps humain qui apparaissent **dès les premiers jours**

THE IMMOBILITY PYRAMID




Mobilisation précoce en réanimation

Effect of early mobilisation on long-term cognitive impairment in critical illness in the USA: a randomised controlled trial

Bhakti K Patel, Krysta S Wolfe, Shruti B Patel, Karen C Dugan, Cheryl L Esbrook, Amy J Pawlik, Megan Stulberg, Crystal Kemple, Megan Teele, Erin Zeleny, Donald Hedeker, Anne S Pohlman, Vineet M Arora, Jesse B Hall, John P Kress

- **Au cours des 96 premières heures de ventilation mécanique**
- **Patients adultes (âgés de ≥ 18 ans) sans déficit fonctionnel et ventilés mécaniquement pour une durée > 24 h**

Single-centre, parallel, randomised controlled trial



Mobilisation précoce en réanimation

Effect of early mobilisation on long-term cognitive impairment in critical illness in the USA: a randomised controlled trial

Bhakti K Patel, Krysta S Wolfe, Shruti B Patel, Karen C Dugan, Cheryl L Esbrook, Amy J Pawlik, Megan Stulberg, Crystal Kemple, Megan Teele, Erin Zeleny, Donald Hedeker, Anne S Pohlman, Vineet M Arora, Jesse B Hall, John P Kress

	Usual care group (n=99)	Intervention group (n=99)
Age, years	54.5 (41.9–64.7)	57.9 (42.3–66.8)
Sex		
Female	44 (44%)	41 (41%)
Male	55 (56%)	58 (59%)
Race		
African American	72 (73%)	68 (69%)
White, non-Hispanic	21 (21%)	26 (26%)
White, Hispanic	4 (4%)	4 (4%)
Asian	2 (2%)	1 (1%)
Barthel Index Score	100 (100–100)	100 (100–100)
BMI, kg/m ²	29.8 (24.2–35.2)	28.2 (23.7–33.1)
Level of education		
High school education or higher	91 (92%)	91 (92%)
Less than high school education	8 (7%)	8 (7%)
APACHE II score	23 (16–27)	23 (18–29)

	Usual care group (n=99)	Intervention group (n=99)
Sepsis*	56 (57%)	63 (64%)
Diabetes	26 (26%)	23 (23%)
Primary diagnosis for ICU admission		
Acute hypoxaemic respiratory failure	35 (35%)	44 (44%)
Acute ventilatory failure	24 (24%)	17 (17%)
Threatened airway	21 (21%)	19 (19%)
Sepsis*	12 (12%)	14 (14%)
Liver failure	3 (3%)	1 (1%)
Gastrointestinal haemorrhage	1 (1%)	2 (2%)
Other	3 (3%)	2 (2%)

Mobilisation précoce en réanimation

Effect of early mobilisation on long-term cognitive impairment in critical illness in the USA: a randomised controlled trial

Bhakti K Patel, Krysta S Wolfe, Shruti B Patel, Karen C Dugan, Cheryl L Esbrook, Amy J Pawlik, Megan Stulberg, Crystal Kemple, Megan Teele, Erin Zeleny, Donald Hedeker, Anne S Pohlman, Vineet M Arora, Jesse B Hall, John P Kress

	Usual care group (n=99)	Intervention group (n=99)	p value
Time from intubation to first PT or OT session (days)	4.7 (3.3–6.8)	1.1 (0.8–2.0)	<0.0001
Number of daily therapy sessions			
Mechanical ventilation	0 (0–0)	2 (1–3)	<0.0001
ICU admission	0 (0–1)	4 (2–6)	<0.001
During hospitalisation	2 (1–4)	5 (3–9)	<0.0001
Delirium duration in ICU (days)	1 (0–3)	0 (0–2)	0.0050
Proportion of ICU days in delirium	25% (0–55.6)	0% (0–28.6)	0.0011
Coma duration in ICU (days)	0 (0–1)	0 (0–0)	0.62
Proportion of ICU days in coma	0% (0–6.3)	0% (0–0)	0.67


Data are median (IQR) or n (%), unless otherwise stated. ICU=intensive care unit. OT=occupational therapy. PT=physical therapy. *Days 1–28. †Home discharge without need for services versus all other discharge possibilities.

Sedation and analgesia			
Patients with propofol infusion	71 (72%)	69 (70%)	0.75
Propofol dose, mg/day	1872.4 (915.2–2803.0)	1259.9 (550.1–2615.0)	0.093
Patients with dexmedetomidine infusion	48 (49%)	48 (49%)	1.00
Dexmedetomidine dose, µg per day	417.8 (99.9–1452.1)	441.7 (221.9–1030.3)	0.97
Patients with benzodiazepine infusion	9 (9%)	12 (12%)	0.49
Benzodiazepine dose, mg per day	21.6 (7.8–39.9)	22.3 (8.1–38.1)	1.00
Patients with opiate infusion	84 (85%)	77 (78%)	0.20
Fentanyl dose, µg per day	1647.2 (652.2–2448.2)	1084.1 (531.1–2404.1)	0.32
Ventilator free days*	24.6 (20.8–26.1)	25.2 (22.9–26.4)	0.18
Duration of mechanical ventilation (days)	3.4 (1.9–6.0)	2.7 (1.6–4.5)	0.11
ICU length of stay (days)	5.6 (2.9–9.8)	4.7 (3.0–8.9)	0.51
Hospital length of stay (days)	9.5 (6.0–17.3)	9.7 (5.9–16.8)	0.70
Discharge destination			
Death	11 (11%)	14 (14%)	..
Hospice	2 (2%)	2 (2%)	..
Outside hospital	4 (4%)	1 (1%)	..
Long-term acute care	7 (7%)	4 (4%)	..
Subacute rehabilitation	10 (10%)	4 (4%)	..
Acute rehabilitation	12 (12%)	12 (12)	..
Home with outpatient therapy	17 (17%)	11 (11%)	..
Home	36 (36%)	51 (52%)	0.032†

Mobilisation précoce en réanimation

Effect of early mobilisation on long-term cognitive impairment in critical illness in the USA: a randomised controlled trial

Bhakti K Patel, Krysta S Wolfe, Shruti B Patel, Karen C Dugan, Cheryl L Esbrook, Amy J Pawlik, Megan Stulberg, Crystal Kemple, Megan Teele, Erin Zeleny, Donald Hedeker, Anne S Pohlman, Vineet M Arora, Jesse B Hall, John P Kress



		0	60	120	180	240	300	360
Number at risk								
Usual care	99	84	81	78	76	75	74	
Early mobilisation	99	81	77	74	73	71	70	

Mobilisation précoce en réanimation

Effect of early mobilisation on long-term cognitive impairment in critical illness in the USA: a randomised controlled trial

Bhakti K Patel, Krysta S Wolfe, Shruti B Patel, Karen C Dugan, Cheryl L Esbrook, Amy J Pawlik, Megan Stulberg, Crystal Kemple, Megan Teele, Erin Zeleny, Donald Hedeker, Anne S Pohlman, Vineet M Arora, Jesse B Hall, John P Kress

	Usual care group (n=99)	Intervention group (n=99)	Absolute difference	p value
Primary outcome				
Cognitive impairment at 1 year	43 (43%)	24 (24%)	-19.2% (-32.1 to -6.3)	0.0043
MoCA* score at 1 year	23 (21-26)	26 (24-28)	3 (1 to 4)	0.0001
Hospital discharge outcome				
Cognitive impairment	68 (69%)	53 (54%)	-15.2% (-28.6 to -1.7)	0.029
MoCA score	20 (16-23)	23 (19-27)	3 (2 to 5)	0.0004
ICU-acquired weakness†	38 (38%)	21 (21%)	-17.1% (-29.7 to -4.7)	0.0083
Total MRC score	49 (44-56)	56 (48-60)	7 (1 to 9)	0.0017
Functional independence	46 (47%)	66 (67%)	20.2% (6.7 to 33.7)	0.0041
Quality of life				
SF-36 physical component score	39.6 (31.8-48.5)	45.7 (29.7-55.6)	4.1 (-0.53 to 8.4)	0.081
Impaired physical health‡	39 (39%)	29 (29%)	-10.1% (-23.3 to 3.1)	0.13
SF-36 mental component score	47.6 (38.3-55.3)	53.3 (44.3-57.2)	5.7 (-0.16 to 6.9)	0.061
Impaired mental health	22 (22%)	13 (13%)	-9.1% (-19.6% to 1.5)	0.094

	Usual care group (n=99)	Intervention group (n=99)	Absolute difference	p value
1-year follow-up				
ICU-acquired weakness	14 (14%)	0	-14.1% (-21.0 to -7.3)	0.0001
Total MRC score	56 (49-60)	58 (56-60)	2 (0 to 4)	0.0073
Functional independence	61 (62%)	64 (65%)	3.0% (-10.4 to 16.5)	0.66
Quality of life				
SF-36 physical component score	41.1 (31.8-49.4)	52.4 (45.3-56.8)	11.3 (6.3 to 13.8)	<0.0001
Impaired physical health	30 (30%)	8 (8%)	-22.2% (-32.7 to -11.7)	0.0001
SF-36 mental component score	55.2 (49.5-59.7)	55.9 (50.2-58.9)	0.7 (-2.7 to 2.3)	0.98
Impaired mental health	9 (9%)	7 (7%)	-2.0% (-9.6 to 5.6)	0.60
Institution-free days	335 (121-356)	338 (111-355)	3 (-8 to 5)	0.88

Data are n (%) or median (IQR), unless otherwise specified. ICU=intensive care unit. MoCA=Montreal Cognitive Assessment. MRC=Medical Research Council. SF-36=Medical Outcomes Study Short Form-36 *MoCA score of less than 26 defined cognitive impairment. †ICU-acquired weakness defined as a combined MRC score of less than 48. ‡At least 1SD below population norms (ie, <40).

Mobilisation précoce en réanimation

Effect of early mobilisation on long-term cognitive impairment in critical illness in the USA: a randomised controlled trial

Bhakti K Patel, Krysta S Wolfe, Shruti B Patel, Karen C Dugan, Cheryl L Esbrook, Amy J Pawlik, Megan Stulberg, Crystal Kemple, Megan Teele, Erin Zeleny, Donald Hedeker, Anne S Pohlman, Vineet M Arora, Jesse B Hall, John P Kress

	Usual care group (n=99)	Intervention group (n=99)	p value
At least one AE due to mobilisation	0 (0%)	6 (6%)	0.029
Type of AE			
Tachycardia	0 (0%)	2 (2%)	1.00
Hypotension	0 (0%)	1 (1%)	1.00
Tachypnoea	0 (0%)	1 (1%)	1.00
Oxygen desaturation	0 (0%)	1 (1%)	1.00
Arterial catheter removal	0 (0%)	1 (1%)	1.00
Rectal tube removal	0 (0%)	1 (1%)	1.00

Data are n (%). More than one adverse event (AE) occurs in one patient.


Mobilisation précoce en réanimation

ORIGINAL ARTICLE

Early Active Mobilization during Mechanical Ventilation in the ICU

The TEAM Study Investigators and the ANZICS Clinical Trials Group*

TEAM trial



Patients adultes sous ventilation mécanique >24h après randomisation et avec un état suffisamment stable pour rendre la mobilisation potentiellement possible.

Minimisation de la sédation et kiné quotidienne

Mobilisation précoce en réanimation

Characteristic	Early Mobilization (N=371)	Usual Care (N=370)
Age — yr	60.5±14.8	59.5±15.2
Female sex — no. (%)	128 (34.5)	146 (39.5)
Body-mass index†	29.9±7.9	30.4±7.8
Frailty and function		
Median score on Clinical Frailty Scale (IQR)‡	3 (2 to 4)	3 (2 to 4)
Median score on Functional Comorbidity Index (IQR)§	2 (1 to 3)	2 (1 to 3)
Median score on WHODAS 2.0 (IQR)¶	10.4 (2.1 to 25.0)	8.7 (2.1 to 22.7)
Highest score on the ICU Mobility Scale in wk before ICU admission	9.9±0.6	9.8±0.7
Median interval from hospital admission to randomization (IQR) — hr	88.3 (50.5 to 137.0)	81.6 (48.2 to 147.0)
Median interval from ICU admission to randomization (IQR) — hr	60.1 (35 to 92.3)	61.3 (33.8 to 96.1)
ICU admission type — no. (%)		
Planned ICU admission after elective surgery	68 (18.3)	58 (15.7)
Unplanned ICU admission	303 (81.7)	312 (84.3)
Median RASS score at randomization (IQR)**	-3 (-4 to -2)	-3 (-4 to -2)
Measurements and interventions at randomization††		
Positive end-expiratory pressure — cm of water	8.9±3.0	8.8±3.1
Pao ₂ :FIO ₂	226±79.1	230±85.2
Receipt of vasopressors by infusion — no. (%)	228 (61.5)	231 (62.4)
Receipt of renal-replacement therapy — no. (%)	82 (22.1)	79 (21.4)
APACHE II score‡‡	18.2±6.8	18±6.9
Diagnosis subgroup — no. (%)§§		
Sepsis¶¶	246 (66.3)	245 (66.2)
Trauma	15 (4.0)	14 (3.8)
Covid-19	7 (1.9)	10 (2.7)


Mobilisation précoce en réanimation

Characteristic	Early Mobilization (N = 371)	Usual Care (N = 370)	Between-Group Difference (95% CI)†
Patients who were assessed by a physiotherapist on day of randomization — no./total no. (%)	320/370 (86.5)	265/363 (73.0)	13.5 (6.7 to 20.3)
No. of days per patient when physiotherapy assessment occurred	0.94±0.11	0.81±0.24	0.14 (0.12 to 0.16)
No. of minutes of active mobilization per day	20.8±14.6	8.8±9.0	12.0 (10.4 to 13.6)
Mobilization milestones‡			
IMS 3 or higher			
Patients — no. (%)	331 (89.2)	330 (89.2)	0 (−4.3 to 4.3)
Median no. of days since randomization (IQR)	3 (1 to 6)	4 (2 to 7)	−1 (−2.2 to −0.2)
IMS 4 or higher			
Patients — no. (%)	287 (77.4)	286 (77.3)	0.1 (−6.0 to 6.1)
Median no. of days since randomization (IQR)	3 (2 to 7)	5 (3 to 8)	−2 (−3.4 to −0.6)
IMS 7 or higher			
Patients — no. (%)	176 (47.4)	150 (40.5)	6.9 (−0.2 to 14.0)
Median no. of days since randomization (IQR)	5 (3 to 8)	7 (4 to 13)	−2 (−3.4 to −0.7)
Median peak IMS (IQR)	6 (4 to 8)	6 (4 to 8)	0 (−1 to 1)


Mobilisation précoce en réanimation

ICU Mobility Scale: 0 (nothing or passive) 1–2 (in-bed or in-chair exercises) 3–4 (active sitting or standing) 5–6 (transfer or marching in place) 7–8 (assisted walking) 9–10 (independent walking)

A Early Mobilization



B Usual Care



Au total, 77 % des patients des deux groupes étaient capables de se tenir debout après un intervalle médian de 3 jours vs 5 jours, respectivement (différence, -2 jours ; IC à 95 %, -3,4 à -0,6).

Mobilisation précoce en réanimation

Outcome	Early Mobilization (N=371)	Usual Care (N=370)	Difference or Odds Ratio (95% CI) [†]	P Value
Primary outcome				
Days alive and out of hospital at day 180 [‡]				
Median no. (IQR)	143 (21 to 161)	145 (51 to 164)	-2.0 (-10 to 6)	0.62
Key secondary outcomes				
Death at day 180				
Patients — no. (%)	83/369 (22.5)	71/364 (19.5)	1.15 (0.81–1.65) [§]	
Median no. of days since randomization (IQR)	17 (9 to 41)	19 (12 to 50)	-2.0 (-12.0 to 8.0)	
Median no. of ventilator-free days at day 28 (IQR)	21 (8 to 25)	21 (11 to 25)	0.0 (-1.4 to 1.4)	
Median no. of ICU-free days at day 28 (IQR)	16 (0 to 21)	17 (3 to 22)	-1.0 (-3.1 to 1.1)	
Functional outcomes in survivors at day 180 [¶]				
Score on EQ-5D-5L utility score	0.7±0.3	0.7±0.3	0.0 (-0.0 to 0.1)	
Score on EQ Visual Analogue Scale ^{**}	70.2±19.7	69.0±20.1	2.0 (-5.7 to 9.7)	
Median score on Barthel Index of ADL (IQR) ^{††}	100 (100 to 100)	100 (95 to 100)	0	
Median score on IADL (IQR) ^{‡‡}	8.0 (7.0 to 8.0)	8.0 (6.0 to 8.0)	0.2 (-0.9 to 1.3)	
Median score on WHODAS 2.0 (IQR) ^{§§}	12.5 (2.1 to 33.3)	14.6 (4.2 to 38.9)	-1.8 (-6.9 to 3.4)	


Mobilisation précoce en réanimation

Adverse events — no. (%) ¶¶


Patients with ≥1 adverse event potentially due to mobilization — no. (%)	34 (9.2)	15 (4.1)	2.55 (1.33–4.89)§	0.005
Adverse events per patient — no. (%)				0.02
0	337 (90.8)	355 (95.9)		
1	19 (5.1)	11 (3.0)		
2	4 (1.1)	2 (0.5)		
≥3	11 (3.0)	2 (0.5)		
Type of adverse events — no. (%)				
Altered blood pressure	13 (3.5)	8 (2.2)		0.27
Cardiac arrhythmia	13 (3.5)	4 (1.1)		0.03
Oxygen desaturation	8 (2.2)	1 (0.3)		0.02
Pain or agitation	4 (1.1)	1 (0.3)		0.37
Removal of invasive line	2 (0.5)	2 (0.5)		1.00
Gastrointestinal	2 (0.5)	1 (0.3)		1.00
Tachypnea	3 (0.8)	0		0.25
Altered neurologic state	1 (0.3)	1 (0.3)		1.00
Other	4 (1.1)	0		0.12

The Effect of Mobilization at 6 Months after Critical Illness — Meta-Analysis

Michelle Paton, M.Phy.,^{1,2} Sarah Chan, D.Phy.,² Claire J. Tipping, Ph.D.,³ Anne Stratton, B.Phy.,³ Ary Serpa Neto, Ph.D.,¹ Rebecca Lane, Ph.D.,⁴ Paul J. Young, Ph.D.,^{1,5,6,7} Lorena Romero, M.B.I.T.,⁸ Carol L. Hodgson, Ph.D.^{1,3,7,9}



Forest Plot Comparison of Days Alive and Out of Hospital to Day 180.



En utilisant des analyses bayésiennes, la probabilité que l'intervention ait augmenté le nombre de jours en vie et hors de l'hôpital était de 75,1 %.


Table 1. Outcomes Including Sensitivity Analyses.*							
Outcome	Studies	Patients/Events	P	I^2	Effect Measure		95% CI
Days alive and out of hospital	6	1121	0.34	41	MD	4.28	−4.46 to 13.03
Low-risk studies only	3	855	0.66	71	MD	3.28	−11.25 to 17.81
Mortality	15	2703	0.47	0	Risk ratio	1.05	0.92 to 1.19
Low-risk studies only	8	1499	0.24	0	Risk ratio	1.11	0.93 to 1.34
Adverse events	5	17,618	0.83	97	Risk ratio	1.13	0.37 to 3.43
Low-risk studies only	4	12,269	0.06	85	Risk ratio	1.94	0.98 to 3.86
PF measured with PROM	7	1109	0.0007	0	SMD	0.2	0.09 to 0.32
Low-risk studies only	4	636	0.3	33	SMD	0.14	−0.12 to 0.4
PF measured in person	6	454	0.11	0	SMD	0.15	−0.03 to 0.34
Low-risk studies only	3	182	0.32	0	SMD	0.15	−0.14 to 0.44
Strength	5	390	0.41	0	SMD	0.08	−0.12 to 0.28
Low-risk studies only	3	164	0.52	0	SMD	−0.1	−0.41 to 0.21
HRQoL							
SF-36 PCS	8	783	0.38	38	MD	1.11	−1.38 to 3.6
SF-36 MCS	8	783	0.57	42	MD	0.77	−1.86 to 3.4
Utility scores	4	772	0.84	0	SMD	−0.01	−0.16 to 0.13

- Probabilité de 95,1 % que l'intervention améliore la fonction physique à 6 mois (différence moyenne standardisée, 0,2 ; intervalle de confiance à 95 %, 0,09 à 0,32 ; I^2 50 %)
- Possibilité de 66,4 % d'augmentation des événements indésirables avec la mise en œuvre de la mobilisation active précoce et une probabilité de 72,2 % d'augmentation de la mortalité à 6 mois


Nutrition en réanimation

The role of nutrition rehabilitation in the recovery of survivors of critical illness: underrecognized and underappreciated

Lesley L. Moisey^{1*}, Judith L. Merriweather² and John W. Drover³



Sepsis et immunoparésie



Levée de sédation précoce en réanimation

Randomized trial of light versus deep sedation on mental health after critical illness*

Randomized, open-label, controlled trial

Miriam M. Treggiari, MD, PhD, MPH; Jacques-André Romand, MD, FCCM; N. David Yanez, PhD; Steven A. Deem, MD; Jack Goldberg, PhD; Leonard Hudson, MD; Claudia-Paula Heidegger, MD; Noel S. Weiss, MD, DrPH

Outcome	ICU Discharge			4 Wks After ICU Discharge		
	Ramsay 1–2 n = 57	Ramsay 3–4 n = 52	<i>p</i>	Ramsay 1–2 n = 52	Ramsay 3–4 n = 50	<i>p</i>
PTSD score, ^b ranks	52 ± 33	57 ± 30	.39	46 ± 29	56 ± 29	.07
PTSD symptom clusters ^c						
Intrusive recollection	19 (41)	13 (36)	.62	9 (20)	9 (23)	.73
Avoidant/numbing	11 (24)	7 (19)	.62	6 (13)	6 (15)	.79
Hyperarousal	19 (41)	16 (44)	.78	5 (11)	10 (26)	.08
Hospital Anxiety and Depression Scale						
Anxiety score	6.4 ± 4.0	7.1 ± 4.6	.37	5.3 ± 4.2	5.0 ± 4.2	.64
Anxiety cases, n (%)	8 (14)	13 (25)	.15	6 (12)	6 (12)	.94
Depression score	5.3 ± 3.4	6.5 ± 4.7	.13	3.4 ± 3.7	3.1 ± 3.7	.72
Depression cases, n (%)	3 (5)	10 (19)	.02	4 (8)	2 (4)	.43

Levée de sédation précoce en réanimation


Randomized trial of light versus deep sedation on mental health after critical illness*

Miriam M. Treggiari, MD, PhD, MPH; Jacques-André Romand, MD, FCCM; N. David Yanez, PhD; Steven A. Deem, MD; Jack Goldberg, PhD; Leonard Hudson, MD; Claudia-Paula Heidegger, MD; Noel S. Weiss, MD, DrPH

Outcome	Sedation Group		<i>p</i> ^a
	Ramsay 1–2 n = 65	Ramsay 3–4 n = 64	
ICU mortality, n (%)	9 (14)	9 (14)	>.99
Hospital mortality, n (%)	12 (18)	11 (17) ^c	.65
Days of mechanical ventilation ^b			
Mean days	2.9 ± 5.0	5.5 ± 10.8	.02
Ventilator-free days			
Days 1–7	6.6	5.7	.02
Days 1–28	27.6	26.6	.03
ICU length of stay ^d	4.0 (1–129)	5.5 (2–99)	.03
ICU-free Days			
Days 1–7	4	1	.03
Days 1–28	24	22	.03
Organ failure to day 7 ^e			
Cardiovascular failure, n (%)	34 (52)	35 (55)	.79
CNS failure, n (%)	16 (25)	20 (31)	.40
Renal failure, n (%)	10 (15)	11 (17)	.78
Hepatic failure, n (%)	9 (14)	4 (6)	.15
Coagulation abnormalities, n (%)	15 (23)	14 (22)	.87
Any organ failure, n (%)	42 (65)	45 (70)	.49
Hospital length of stay ^d	16 (12.5–32.5)	20 (13–38)	.47
Hospital-free days, days 1–28	8.5	6.0	.42




Comfort and patient-centred care without excessive sedation: the eCASH concept






Comfort and patient-centred care
without excessive sedation: the eCASH concept

Approche
multidisciplinaire de
prise en charge
**globale centré sur le
patient**




Active and passive compliance in an enhanced recovery programme


Active compliance vs. major morbidity




Active compliance vs. prolonged LOS



Passive compliance vs. major morbidity



Passive compliance vs. prolonged LOS



Programme ERAS en réanimation ?



ERAS® GUIDELINES
AND EIAS
PROTOCOLS

ERAS® Benefits

\$\$\$

FOR THE HOSPITAL

- Optimization of a complex care chain
- Increased staff satisfaction
- Reduced nursing workload
- Fewer re-admissions
- Great savings
- Recoup resources

FOR THE PATIENT

- Structured information & participation in the care process
- Patient empowerment
- Fewer serious complications
- Shorter length of stay
- Enhanced recovery
- Improved survival



The ERAS® Interactive Audit System (EIAS)

[Read more](#)




The ERAS® Implementation Program (EIP)

[Read more](#)

Programme ERAS en réanimation ?

CONTINUOUSLY
IMPROVE AND
LEARN

With Our Data-Driven Digital Platform
and Multi-Disciplinary Training



Implémentation de « bundles » en réanimation ?

Staff education, regular sedation and analgesia quality feedback, and a sedation monitoring technology for improving sedation and analgesia quality for critically ill, mechanically ventilated patients: a cluster randomised trial

De nombreux cliniciens ont trouvé le suivi utile, mais il n'a souvent pas été utilisé pour la prise de décision. La formation a été appréciée et jugée utile par le personnel.

En revanche, le retour d'information sur la qualité de la sédation et de l'analgésie a été mal compris et jugé peu pertinent pour la pratique infirmière au chevet du patient.

Cluster randomised trial in eight ICUs

	Education	Process feedback	Responsiveness monitoring
Patient-level sedation–analgesia quality outcomes (RR)			
Optimal sedation	1.02 (0.92–1.13)	0.90 (0.80–1.01)	1.17 (1.04–1.31)*
Free from excessive sedation	1.02 (0.96–1.08)	0.90 (0.84–0.97)*	1.09 (1.01–1.17)*
Free from agitation	1.02 (0.96–1.08)	1.02 (0.95–1.09)	0.98 (0.91–1.05)
Free from poor relaxation	0.98 (0.92–1.04)	0.98 (0.91–1.05)	1.05 (0.98–1.13)
Free from poor synchronisation	1.00 (0.95–1.07)	0.99 (0.92–1.06)	1.04 (0.97–1.11)
Sedative and analgesic drug use			
Propofol equivalents used (RoGM)	1.09 (0.85–1.40)	1.01 (0.77–1.34)	1.01 (0.76–1.34)
Alfentanil equivalents used (RoGM)	1.06 (0.83–1.35)	1.05 (0.80–1.38)	1.18 (0.90–1.55)
Days on which patient received ≥ 4000 mg propofol (or equivalents) administered (OR)	0.43 (0.22–0.86)*	2.45 (1.11–5.42)*	1.11 (0.52–2.38)
Patient received haloperidol (OR)	1.18 (0.74–1.89)	0.95 (0.56–1.63)	1.14 (0.68–1.91)
Mortality (OR)			
ICU	1.19 (0.73–1.93)	1.33 (0.77–2.29)	0.78 (0.46–1.35)
Hospital	1.08 (0.68–1.72)	1.08 (0.65–1.81)	0.82 (0.50–1.37)
Time-to-event outcomes (HR)			
Cessation of mechanical ventilation	0.92 (0.76–1.12)	1.00 (0.80–1.24)	0.87 (0.70–1.08)
Discharge from ICU	0.89 (0.71–1.11)	0.98 (0.77–1.26)	0.92 (0.71–1.17)
Discharge from hospital	0.88 (0.70–1.11)	1.15 (0.89–1.48)	1.03 (0.79–1.33)

Implémentation de « bundles » en réanimation ?



Effect of ICU care bundles on long-term patient-relevant outcomes: a scoping review

Effets à long terme sur la qualité de vie, la qualité de vie des patients et « PICS » indéterminés


Bundle category	Outcome	Effect		
		Positive	Possibly positive	None
All (n=38)	Survival	13 ^{44 45 54 55 59 64-67 70 71 74 76}	2 ^{60 61}	9 ^{39 46 48 56 57 63 68 69 75}
	Care-related outcomes *	12 ^{39 42 49-51 53 55 57-59 70 75}	4 ^{43 47 61 62}	5 ^{41 48 69 73 74}
	Health-related quality of life	2 ^{59 73}	2 ^{42 62}	1 ⁵²
	PICS—physical health	3 ^{56 61 69}		2 ^{52 68}
	PICS—cognition	1 ⁵⁶		3 ^{40 52 68}
	PICS—mental health	2 ^{72 73}		1 ⁶¹
	Adverse events			1 ⁶⁹
	Social health			1 ⁷³
Communication (n=4)	Survival			1 ³⁹
	Care-related outcomes*	2 ^{39 51}	1 ⁴⁷	
	PICS—mental health	1 ⁷²		
Early rehabilitation (n=3)	Survival			3 ^{56 68 69}
	Care-related outcomes*			1 ⁶⁹
	PICS—physical health	2 ^{56 69}		1 ⁶⁸
	PICS—cognition	1 ⁵⁶		1 ⁶⁸
	Adverse events			1 ⁶⁹
Neurocognitive (n=6)	Survival	2 ^{59 70}		1 ⁷⁵
	Care-related outcomes*	3 ^{59 70 75}		1 ⁷³
	Health-related quality of life	2 ^{59 73}		1 ⁵²
	PICS—physical health			1 ⁵²
	PICS—cognition			2 ^{40 52}
	PICS—mental health	1 ⁷³		
Pharmacological discontinuation (n=3)	Survival			1 ⁴⁸
	Care-related outcomes*	2 ^{49 58}		1 ⁴⁸
Sepsis (n=11)	Survival	10 ^{44 45 54 64-67 71 74 76}		1 ⁶³
	Care-related outcomes*			1 ⁷⁴
Ventilation (n=2)	Survival	1 ⁵⁵		1 ⁵⁷
	Care-related outcomes*	2 ^{55 57}		

Implémentation de « bundles » en réanimation ?

Effectiveness of an intensive care telehealth programme to improve process quality (ERIC): a multicentre stepped wedge cluster randomised controlled trial



Un programme télémédical d'amélioration de la qualité a permis d'améliorer l'adhésion à sept indicateurs de performance allemands en réanimation




**Bénéfice
thérapeutique**



iatrogénie


Ensemble des conséquences néfastes sur l'état de santé individuel ou collectif de tout acte ou mesure pratiqué ou prescrit par un professionnel de santé habilité et qui vise à préserver, améliorer ou rétablir la santé.



Feasibility of mobilisation in ICU: a multi-centre point prevalence study of mobility practices in the UK

Risque calculé pour
chaque défaillance
d'organe et l'état de
la mobilité

Proportion de patients mobilisés dans les 48-72 heures,
selon leur état physiologique





réanimation 2023

PARIS 14-16 JUIN

Palais des Congrès de Paris
Porte Maillot

Merci de votre attention